inclusion criteria: 1. provide informed consent before participation in the study. 2. aged ≥18 years 3. hospital admission with symptoms suggestive of covid-19 infection 4. ten days or less since the onset of symptoms 5. virological confirmation of sars-cov2 infection by reverse transcriptase pcr (rt- pcr) according to center for disease control and prevention (cdc) guidelines within the previous 72 hours 6. subjects showing bilateral pulmonary infiltrates on chest imaging 7. saturation of oxygen (spo2) by pulse oximetry \<94% on room air at sea level. 8. female subjects must meet one of the following: * if of childbearing potential, female subjects must have a negative urine pregnancy test at screening and must also be willing to practice total abstinence or to use an approved (non-hormonal) form of birth-control throughout the study treatment phase and up to 28 days after the last study drug dose if randomized to apabetalone." -or- * meet at least one of the following criteria: * be postmenopausal, defined as having been amenorrheic for at least 2 years * have had a hysterectomy or a bilateral oophorectomy

inclusion criteria: 1. provide informed consent before participation in the study. 2. aged ≥18 years 3. hospital admission with symptoms suggestive of covid-19 infection 4. ten days or less since the onset of symptoms 5. virological confirmation of sars-cov2 infection by reverse transcriptase pcr (rt- pcr) according to center for disease control and prevention (cdc) guidelines within the previous 72 hours 6. subjects showing bilateral pulmonary infiltrates on chest imaging 7. saturation of oxygen (spo2) by pulse oximetry \<94% on room air at sea level. 8. female subjects must meet one of the following: * if of childbearing potential, female subjects must have a negative urine pregnancy test at screening and must also be willing to practice total abstinence or to use an approved (non-hormonal) form of birth-control throughout the study treatment phase and up to 28 days after the last study drug dose if randomized to apabetalone." -or- * meet at least one of the following criteria: * be postmenopausal, defined as having been amenorrheic for at least 2 years * have had a hysterectomy or a bilateral oophorectomy

inclusion criteria: provide informed consent before participation in the study. aged ≥18 years hospital admission with symptoms suggestive of covid-19 infection ten days or less since the onset of symptoms virological confirmation of sars-cov2 infection by reverse transcriptase pcr (rt- pcr) according to center for disease control and prevention (cdc) guidelines within the previous 72 hours subjects showing bilateral pulmonary infiltrates on chest imaging saturation of oxygen (spo2) by pulse oximetry <94% on room air at sea level. female subjects must meet one of the following: if of childbearing potential, female subjects must have a negative urine pregnancy test at screening and must also be willing to practice total abstinence or to use an approved (non-hormonal) form of birth-control throughout the study treatment phase and up to 28 days after the last study drug dose if randomized to apabetalone." -or- meet at least one of the following criteria: be postmenopausal, defined as having been amenorrheic for at least 2 years have had a hysterectomy or a bilateral oophorectomy

inclusion criteria: provide informed consent before participation in the study. aged ≥18 years hospital admission with symptoms suggestive of covid-19 infection ten days or less since the onset of symptoms virological confirmation of sars-cov2 infection by reverse transcriptase pcr (rt- pcr) according to center for disease control and prevention (cdc) guidelines within the previous 72 hours subjects showing bilateral pulmonary infiltrates on chest imaging saturation of oxygen (spo2) by pulse oximetry <94% on room air at sea level. female subjects must meet one of the following: if of childbearing potential, female subjects must have a negative urine pregnancy test at screening and must also be willing to practice total abstinence or to use an approved (non-hormonal) form of birth-control throughout the study treatment phase and up to 28 days after the last study drug dose if randomized to apabetalone." -or- meet at least one of the following criteria: be postmenopausal, defined as having been amenorrheic for at least 2 years have had a hysterectomy or a bilateral oophorectomy

inclusion criteria: 1. provide informed consent before participation in the study. 2. aged ≥18 years 3. hospital admission with symptoms suggestive of covid-19 infection 4. ten days or less since the onset of symptoms 5. virological confirmation of sars-cov2 infection by reverse transcriptase pcr (rt- pcr) according to center for disease control and prevention (cdc) guidelines within the previous 72 hours 6. subjects showing bilateral pulmonary infiltrates on chest imaging 7. saturation of oxygen (spo2) by pulse oximetry <94% on room air at sea level. 8. female subjects must meet one of the following: - if of childbearing potential, female subjects must have a negative urine pregnancy test at screening and must also be willing to practice total abstinence or to use an approved (non-hormonal) form of birth-control throughout the study treatment phase and up to 28 days after the last study drug dose if randomized to apabetalone." -or- - meet at least one of the following criteria: - be postmenopausal, defined as having been amenorrheic for at least 2 years - have had a hysterectomy or a bilateral oophorectomy

inclusion criteria: 1. provide informed consent before participation in the study. 2. aged ≥18 years 3. hospital admission with symptoms suggestive of covid-19 infection 4. ten days or less since the onset of symptoms 5. virological confirmation of sars-cov2 infection by reverse transcriptase pcr (rt- pcr) according to center for disease control and prevention (cdc) guidelines within the previous 72 hours 6. subjects showing bilateral pulmonary infiltrates on chest imaging 7. saturation of oxygen (spo2) by pulse oximetry <94% on room air at sea level. 8. female subjects must meet one of the following: - if of childbearing potential, female subjects must have a negative urine pregnancy test at screening and must also be willing to practice total abstinence or to use an approved (non-hormonal) form of birth-control throughout the study treatment phase and up to 28 days after the last study drug dose if randomized to apabetalone." -or- - meet at least one of the following criteria: - be postmenopausal, defined as having been amenorrheic for at least 2 years - have had a hysterectomy or a bilateral oophorectomy